Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Yoshitaka, Hosaka"'
Autor:
Chika Higashi, Yoshitaka Hosaka, Junichi Sakaki, Naoto Tsuda, Masaki Nakamura, Mitsuhiro Takagi, Atsuko Kawaji
Publikováno v:
Drug Development Research. 79:16-21
Preclinical Research & Development MR1704 is a selective G protein-coupled receptor 40/free fatty acid receptor 1 agonist, which exhibited favorable pharmacokinetic profiles and glucose-lowering effects in animal models. We studied the effects of MR1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd46946e905aeb60745a2246d30c161f
https://doi.org/10.1002/ddr.21416
https://doi.org/10.1002/ddr.21416
Autor:
Makoto Ikejiri, Naoyuki Katayama, Koshi Ohishi, Yoshitaka Hosaka, Hideo Wada, Katsuki Naitoh, Yoshiki Yamashita, Masakatsu Nishikawa, Takeshi Mastumoto
Publikováno v:
Thrombosis Research. 133:440-444
Background Thrombotic microangiopathy (TMA) is caused by various conditions, such as decreased a ADAMTS13 level, activated or injured vascular endothelial cells or activated platelets. This study examined the soluble platelet glycoprotein VI (sGPVI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae1b33a65cf8d4c52af5b56336bd99c
https://doi.org/10.1016/j.thromres.2013.11.023
https://doi.org/10.1016/j.thromres.2013.11.023
Autor:
Jiro Hirose, Masaki Nakamura, Shoji Furusako, Tetsushi Kawahara, Yoshitaka Hosaka, Takashi Takeuchi, Kazuyuki Nakayama
Publikováno v:
European journal of pharmacology. 802
Severe sepsis is a complex, multifactorial, and rapidly progressing disease characterized by excessive inflammation and coagulation following bacterial infection. To simultaneously suppress pro-inflammatory and pro-coagulant responses, we genetically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94681c2024347ebac7da742318451c7b
https://pubmed.ncbi.nlm.nih.gov/28249709
https://pubmed.ncbi.nlm.nih.gov/28249709
Autor:
Harold B. Wood, Shunsuke Shimada, Hiroshi Nagasue, Takashi Mizuno, Tomokazu Hirabayashi, Toshiya Endo, Shigeki Matsumoto, Yutaka Kato, Shoji Furusako, Katsuyoshi Hikita, Ting Zhang, Keiko Taguchi, Yoshitaka Maeda, Kazunari Nakao, Alan Hruza, Paul Reichert, Isao Sakurada, Teruyuki Nishimura, Tooru Yokoyama, Yoshitaka Hosaka, Mikihiko Shinozaki, Katsutoshi Takeuchi
Publikováno v:
Bioorganicmedicinal chemistry letters. 27(11)
Using structure based drug design, novel aminobenzisoxazoles as coagulation factor IXa inhibitors were designed and synthesized. Highly selective inhibition of FIXa over FXa was demonstrated. Anticoagulation profile of selected compounds was evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eacba671268d284c0b15e929dbcd5d6
https://pubmed.ncbi.nlm.nih.gov/28408226
https://pubmed.ncbi.nlm.nih.gov/28408226
Publikováno v:
Journal of Biophysical Chemistry. :132-141
The light chain of inter-α inhibitor, also known as bikunin or urinary trypsin inhibitor, is composed of two tandemly arranged Kunitz-type protease inhibitor domains. The second domain of bikunin has factor Xa inhibitory activity which previously wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42ca16091902c1aad17d84c162583b89
https://doi.org/10.4236/jbpc.2012.32015
https://doi.org/10.4236/jbpc.2012.32015
Autor:
Fumihiko Saitoh, Hidemitsu Nishida, Yoshitaka Hosaka, Munetaka Ohkouchi, Naoto Kosuga, Ikuya Shiromizu, Tomokazu Matsusue, Ichiro Yamamoto, Miwa Matsumoto, Takafumi Mukaihira
Publikováno v:
Chemical and Pharmaceutical Bulletin. 55:317-323
In the course of development of factor Xa (FXa) inhibitors, we have found unique compounds containing an N,O- and an N,N-spiro acetal structure. It appeared that the difference in overall conformation due to the N,X-spiro acetal structure might be im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b781fed7c810a4e565ae830ee7f451b
https://doi.org/10.1248/cpb.55.317
https://doi.org/10.1248/cpb.55.317
Autor:
Masatsugu Kamiya, Hidemistu Nishida, Mikihiko Shinozaki, Hidemi Ishii, Tamami Ohno, Tomokazu Matsusue, Yukiko Yatagai, Miwa Matsumoto, Kiyoshi Mizuguchi, Misao Kurokawa, Yoshitaka Hosaka
Publikováno v:
European Journal of Pharmacology. 529:164-171
Factor Xa plays an important role in blood coagulation and is widely regarded as an attractive target for antithrombotic drug development. M55551 and M55165 (1-arylsulfonyl-3-piperazinone derivatives) are novel synthetic factor Xa inhibitors. In vitr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8a14ecebb912af239117277ef92b80
https://doi.org/10.1016/j.ejphar.2005.11.002
https://doi.org/10.1016/j.ejphar.2005.11.002
Autor:
Fumihiko Saitoh, Hidenori Mochizuki, Atsushi Okamoto, Hidemitsu Nishida, Yoshitaka Hosaka, Hiroyasu Shimada, Tomokazu Matsusue, Yutaka Miyazaki, Takafumi Mukaihira, Kazuhiro Suzuki, Masashi Mizuno, Miwa Matsumoto, Shuhei Ohnishi
Publikováno v:
Chemical and Pharmaceutical Bulletin. 52:459-462
Compounds containing an ethylenediamine structure in place of the piperazine ring of M55113 (1) and M55551 (2) were synthesized to investigate the effects of a piperazine moiety and evaluated for activity as factor Xa (FXa) inhibitors. Most such comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96901fe22bd499b167748b2c8c5337a9
https://doi.org/10.1248/cpb.52.459
https://doi.org/10.1248/cpb.52.459
Autor:
Hidemitsu Nishida, Yoshitaka Hosaka, Harada Kousuke, Manabu Itoh, Aki Muraoka, Hidenori Mochizuki, Tomokazu Matsusue, Fumihiko Saitoh, Miwa Matsumoto, Miyuki Fukui, Shuhei Ohnishi, Atsushi Okamoto, Takafumi Mukaihira, Yutaka Miyazaki
Publikováno v:
Chemical and Pharmaceutical Bulletin. 50:1187-1194
Intravascular clot formation is an important event in a number of cardiovascular diseases. The prevention of blood coagulation has become a major target for new therapeutic agents. Factor Xa (FXa) is a trypsin-like serine protease that plays a key ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9bc367a4c2a5079d0ff7aa49a511ecc
https://doi.org/10.1248/cpb.50.1187
https://doi.org/10.1248/cpb.50.1187
Autor:
Shoji Furusako, Kumiko Ogawa, Kamon Shirakawa, Motoyasu Honda, Katsuki Naitoh, Yoshitaka Hosaka
Publikováno v:
Platelets. 26(8)
Glycoprotein VI (GPVI) plays a critical role in the platelet response to collagen. Clinical studies suggest that the plasma level of soluble GPVI (sGPVI) is a highly specific and useful platelet activation marker. However, many properties of sGPVI ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b858e23fef33348b28527f615931a76
https://pubmed.ncbi.nlm.nih.gov/25549161
https://pubmed.ncbi.nlm.nih.gov/25549161